 | • レポートコード：MRC2-11QY12501 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は白血病のグローバル市場について調査・分析したレポートです。種類別（急性骨髄性白血病（AML）、慢性骨髄性白血病（CML）、急性リンパ芽球性白血病（ALL）、慢性リンパ性白血病（CLL））市場規模、用途別（化学療法、放射線療法、標的療法、生物学的療法、幹細胞移植）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別白血病の競争状況、市場シェア ・世界の白血病市場：種類別市場規模 2015年-2020年（急性骨髄性白血病（AML）、慢性骨髄性白血病（CML）、急性リンパ芽球性白血病（ALL）、慢性リンパ性白血病（CLL）） ・世界の白血病市場：種類別市場規模予測 2021年-2026年（急性骨髄性白血病（AML）、慢性骨髄性白血病（CML）、急性リンパ芽球性白血病（ALL）、慢性リンパ性白血病（CLL）） ・世界の白血病市場：用途別市場規模 2015年-2020年（化学療法、放射線療法、標的療法、生物学的療法、幹細胞移植） ・世界の白血病市場：用途別市場規模予測 2021年-2026年（化学療法、放射線療法、標的療法、生物学的療法、幹細胞移植） ・北米の白血病市場分析：米国、カナダ ・ヨーロッパの白血病市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの白血病市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の白血病市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの白血病市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Biogen、GSK、Novartis、Pfizer、Roche、Takeda Oncology、Teva Pharmaceutical、Celgene、Daiichi Sankyo、EISAI、Sunesis Pharmaceuticals、Bristol-Myers Squibb、Spectrum Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Leukemia is a group ofcancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells.
High incidence rate of blood cancers and rise in incidence of leukaemia across the globe will drive the leukemia market.
Market Analysis and Insights: Global Leukemia Cancer Market
The global Leukemia Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Leukemia Cancer Scope and Market Size
Leukemia Cancer market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Leukemia Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Biogen
GSK
Novartis
Pfizer
Roche
Takeda Oncology
Teva Pharmaceutical
Celgene
Daiichi Sankyo
EISAI
Sunesis Pharmaceuticals
Bristol-Myers Squibb
Spectrum Pharmaceuticals
Market segment by Type, the product can be split into
Acute Myeloid Leukaemia (AML)
Chronic Myeloid Leukaemia (CML)
Acute Lymphoblastic Leukaemia (ALL)
Chronic Lymphocytic Leukaemia (CLL)
Market segment by Application, split into
Chemotherapy
Radiation Therapy
Targeted Therapy
Biological Therapy
Stem Cell Transplant
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Leukemia Cancer Revenue
1.4 Market by Type
1.4.1 Global Leukemia Cancer Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Acute Myeloid Leukaemia (AML)
1.4.3 Chronic Myeloid Leukaemia (CML)
1.4.4 Acute Lymphoblastic Leukaemia (ALL)
1.4.5 Chronic Lymphocytic Leukaemia (CLL)
1.5 Market by Application
1.5.1 Global Leukemia Cancer Market Share by Application: 2020 VS 2026
1.5.2 Chemotherapy
1.5.3 Radiation Therapy
1.5.4 Targeted Therapy
1.5.5 Biological Therapy
1.5.6 Stem Cell Transplant
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Leukemia Cancer Market Perspective (2015-2026)
2.2 Global Leukemia Cancer Growth Trends by Regions
2.2.1 Leukemia Cancer Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Leukemia Cancer Historic Market Share by Regions (2015-2020)
2.2.3 Leukemia Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Leukemia Cancer Market Growth Strategy
2.3.6 Primary Interviews with Key Leukemia Cancer Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Leukemia Cancer Players by Market Size
3.1.1 Global Top Leukemia Cancer Players by Revenue (2015-2020)
3.1.2 Global Leukemia Cancer Revenue Market Share by Players (2015-2020)
3.1.3 Global Leukemia Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Leukemia Cancer Market Concentration Ratio
3.2.1 Global Leukemia Cancer Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Leukemia Cancer Revenue in 2019
3.3 Leukemia Cancer Key Players Head office and Area Served
3.4 Key Players Leukemia Cancer Product Solution and Service
3.5 Date of Enter into Leukemia Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Leukemia Cancer Historic Market Size by Type (2015-2020)
4.2 Global Leukemia Cancer Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Leukemia Cancer Market Size by Application (2015-2020)
5.2 Global Leukemia Cancer Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Leukemia Cancer Market Size (2015-2020)
6.2 Leukemia Cancer Key Players in North America (2019-2020)
6.3 North America Leukemia Cancer Market Size by Type (2015-2020)
6.4 North America Leukemia Cancer Market Size by Application (2015-2020)
7 Europe
7.1 Europe Leukemia Cancer Market Size (2015-2020)
7.2 Leukemia Cancer Key Players in Europe (2019-2020)
7.3 Europe Leukemia Cancer Market Size by Type (2015-2020)
7.4 Europe Leukemia Cancer Market Size by Application (2015-2020)
8 China
8.1 China Leukemia Cancer Market Size (2015-2020)
8.2 Leukemia Cancer Key Players in China (2019-2020)
8.3 China Leukemia Cancer Market Size by Type (2015-2020)
8.4 China Leukemia Cancer Market Size by Application (2015-2020)
9 Japan
9.1 Japan Leukemia Cancer Market Size (2015-2020)
9.2 Leukemia Cancer Key Players in Japan (2019-2020)
9.3 Japan Leukemia Cancer Market Size by Type (2015-2020)
9.4 Japan Leukemia Cancer Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Leukemia Cancer Market Size (2015-2020)
10.2 Leukemia Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Leukemia Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia Leukemia Cancer Market Size by Application (2015-2020)
11 India
11.1 India Leukemia Cancer Market Size (2015-2020)
11.2 Leukemia Cancer Key Players in India (2019-2020)
11.3 India Leukemia Cancer Market Size by Type (2015-2020)
11.4 India Leukemia Cancer Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Leukemia Cancer Market Size (2015-2020)
12.2 Leukemia Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America Leukemia Cancer Market Size by Type (2015-2020)
12.4 Central & South America Leukemia Cancer Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Biogen
13.1.1 Biogen Company Details
13.1.2 Biogen Business Overview
13.1.3 Biogen Leukemia Cancer Introduction
13.1.4 Biogen Revenue in Leukemia Cancer Business (2015-2020))
13.1.5 Biogen Recent Development
13.2 GSK
13.2.1 GSK Company Details
13.2.2 GSK Business Overview
13.2.3 GSK Leukemia Cancer Introduction
13.2.4 GSK Revenue in Leukemia Cancer Business (2015-2020)
13.2.5 GSK Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Leukemia Cancer Introduction
13.3.4 Novartis Revenue in Leukemia Cancer Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Leukemia Cancer Introduction
13.4.4 Pfizer Revenue in Leukemia Cancer Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Roche
13.5.1 Roche Company Details
13.5.2 Roche Business Overview
13.5.3 Roche Leukemia Cancer Introduction
13.5.4 Roche Revenue in Leukemia Cancer Business (2015-2020)
13.5.5 Roche Recent Development
13.6 Takeda Oncology
13.6.1 Takeda Oncology Company Details
13.6.2 Takeda Oncology Business Overview
13.6.3 Takeda Oncology Leukemia Cancer Introduction
13.6.4 Takeda Oncology Revenue in Leukemia Cancer Business (2015-2020)
13.6.5 Takeda Oncology Recent Development
13.7 Teva Pharmaceutical
13.7.1 Teva Pharmaceutical Company Details
13.7.2 Teva Pharmaceutical Business Overview
13.7.3 Teva Pharmaceutical Leukemia Cancer Introduction
13.7.4 Teva Pharmaceutical Revenue in Leukemia Cancer Business (2015-2020)
13.7.5 Teva Pharmaceutical Recent Development
13.8 Celgene
13.8.1 Celgene Company Details
13.8.2 Celgene Business Overview
13.8.3 Celgene Leukemia Cancer Introduction
13.8.4 Celgene Revenue in Leukemia Cancer Business (2015-2020)
13.8.5 Celgene Recent Development
13.9 Daiichi Sankyo
13.9.1 Daiichi Sankyo Company Details
13.9.2 Daiichi Sankyo Business Overview
13.9.3 Daiichi Sankyo Leukemia Cancer Introduction
13.9.4 Daiichi Sankyo Revenue in Leukemia Cancer Business (2015-2020)
13.9.5 Daiichi Sankyo Recent Development
13.10 EISAI
13.10.1 EISAI Company Details
13.10.2 EISAI Business Overview
13.10.3 EISAI Leukemia Cancer Introduction
13.10.4 EISAI Revenue in Leukemia Cancer Business (2015-2020)
13.10.5 EISAI Recent Development
13.11 Sunesis Pharmaceuticals
10.11.1 Sunesis Pharmaceuticals Company Details
10.11.2 Sunesis Pharmaceuticals Business Overview
10.11.3 Sunesis Pharmaceuticals Leukemia Cancer Introduction
10.11.4 Sunesis Pharmaceuticals Revenue in Leukemia Cancer Business (2015-2020)
10.11.5 Sunesis Pharmaceuticals Recent Development
13.12 Bristol-Myers Squibb
10.12.1 Bristol-Myers Squibb Company Details
10.12.2 Bristol-Myers Squibb Business Overview
10.12.3 Bristol-Myers Squibb Leukemia Cancer Introduction
10.12.4 Bristol-Myers Squibb Revenue in Leukemia Cancer Business (2015-2020)
10.12.5 Bristol-Myers Squibb Recent Development
13.13 Spectrum Pharmaceuticals
10.13.1 Spectrum Pharmaceuticals Company Details
10.13.2 Spectrum Pharmaceuticals Business Overview
10.13.3 Spectrum Pharmaceuticals Leukemia Cancer Introduction
10.13.4 Spectrum Pharmaceuticals Revenue in Leukemia Cancer Business (2015-2020)
10.13.5 Spectrum Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Leukemia Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by Leukemia Cancer Revenue
Table 3. Ranking of Global Top Leukemia Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Leukemia Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Acute Myeloid Leukaemia (AML)
Table 6. Key Players of Chronic Myeloid Leukaemia (CML)
Table 7. Key Players of Acute Lymphoblastic Leukaemia (ALL)
Table 8. Key Players of Chronic Lymphocytic Leukaemia (CLL)
Table 9. Global Leukemia Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Leukemia Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Leukemia Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Leukemia Cancer Market Share by Regions (2015-2020)
Table 13. Global Leukemia Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Leukemia Cancer Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Leukemia Cancer Market Growth Strategy
Table 19. Main Points Interviewed from Key Leukemia Cancer Players
Table 20. Global Leukemia Cancer Revenue by Players (2015-2020) (Million US$)
Table 21. Global Leukemia Cancer Market Share by Players (2015-2020)
Table 22. Global Top Leukemia Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leukemia Cancer as of 2019)
Table 23. Global Leukemia Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Leukemia Cancer Product Solution and Service
Table 26. Date of Enter into Leukemia Cancer Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Leukemia Cancer Market Size by Type (2015-2020) (Million US$)
Table 29. Global Leukemia Cancer Market Size Share by Type (2015-2020)
Table 30. Global Leukemia Cancer Revenue Market Share by Type (2021-2026)
Table 31. Global Leukemia Cancer Market Size Share by Application (2015-2020)
Table 32. Global Leukemia Cancer Market Size by Application (2015-2020) (Million US$)
Table 33. Global Leukemia Cancer Market Size Share by Application (2021-2026)
Table 34. North America Key Players Leukemia Cancer Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Leukemia Cancer Market Share (2019-2020)
Table 36. North America Leukemia Cancer Market Size by Type (2015-2020) (Million US$)
Table 37. North America Leukemia Cancer Market Share by Type (2015-2020)
Table 38. North America Leukemia Cancer Market Size by Application (2015-2020) (Million US$)
Table 39. North America Leukemia Cancer Market Share by Application (2015-2020)
Table 40. Europe Key Players Leukemia Cancer Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Leukemia Cancer Market Share (2019-2020)
Table 42. Europe Leukemia Cancer Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Leukemia Cancer Market Share by Type (2015-2020)
Table 44. Europe Leukemia Cancer Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Leukemia Cancer Market Share by Application (2015-2020)
Table 46. China Key Players Leukemia Cancer Revenue (2019-2020) (Million US$)
Table 47. China Key Players Leukemia Cancer Market Share (2019-2020)
Table 48. China Leukemia Cancer Market Size by Type (2015-2020) (Million US$)
Table 49. China Leukemia Cancer Market Share by Type (2015-2020)
Table 50. China Leukemia Cancer Market Size by Application (2015-2020) (Million US$)
Table 51. China Leukemia Cancer Market Share by Application (2015-2020)
Table 52. Japan Key Players Leukemia Cancer Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Leukemia Cancer Market Share (2019-2020)
Table 54. Japan Leukemia Cancer Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Leukemia Cancer Market Share by Type (2015-2020)
Table 56. Japan Leukemia Cancer Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Leukemia Cancer Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Leukemia Cancer Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Leukemia Cancer Market Share (2019-2020)
Table 60. Southeast Asia Leukemia Cancer Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Leukemia Cancer Market Share by Type (2015-2020)
Table 62. Southeast Asia Leukemia Cancer Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Leukemia Cancer Market Share by Application (2015-2020)
Table 64. India Key Players Leukemia Cancer Revenue (2019-2020) (Million US$)
Table 65. India Key Players Leukemia Cancer Market Share (2019-2020)
Table 66. India Leukemia Cancer Market Size by Type (2015-2020) (Million US$)
Table 67. India Leukemia Cancer Market Share by Type (2015-2020)
Table 68. India Leukemia Cancer Market Size by Application (2015-2020) (Million US$)
Table 69. India Leukemia Cancer Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Leukemia Cancer Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Leukemia Cancer Market Share (2019-2020)
Table 72. Central & South America Leukemia Cancer Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Leukemia Cancer Market Share by Type (2015-2020)
Table 74. Central & South America Leukemia Cancer Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Leukemia Cancer Market Share by Application (2015-2020)
Table 76. Biogen Company Details
Table 77. Biogen Business Overview
Table 78. Biogen Product
Table 79. Biogen Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 80. Biogen Recent Development
Table 81. GSK Company Details
Table 82. GSK Business Overview
Table 83. GSK Product
Table 84. GSK Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 85. GSK Recent Development
Table 86. Novartis Company Details
Table 87. Novartis Business Overview
Table 88. Novartis Product
Table 89. Novartis Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 90. Novartis Recent Development
Table 91. Pfizer Company Details
Table 92. Pfizer Business Overview
Table 93. Pfizer Product
Table 94. Pfizer Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 95. Pfizer Recent Development
Table 96. Roche Company Details
Table 97. Roche Business Overview
Table 98. Roche Product
Table 99. Roche Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 100. Roche Recent Development
Table 101. Takeda Oncology Company Details
Table 102. Takeda Oncology Business Overview
Table 103. Takeda Oncology Product
Table 104. Takeda Oncology Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 105. Takeda Oncology Recent Development
Table 106. Teva Pharmaceutical Company Details
Table 107. Teva Pharmaceutical Business Overview
Table 108. Teva Pharmaceutical Product
Table 109. Teva Pharmaceutical Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 110. Teva Pharmaceutical Recent Development
Table 111. Celgene Business Overview
Table 112. Celgene Product
Table 113. Celgene Company Details
Table 114. Celgene Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 115. Celgene Recent Development
Table 116. Daiichi Sankyo Company Details
Table 117. Daiichi Sankyo Business Overview
Table 118. Daiichi Sankyo Product
Table 119. Daiichi Sankyo Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 120. Daiichi Sankyo Recent Development
Table 121. EISAI Company Details
Table 122. EISAI Business Overview
Table 123. EISAI Product
Table 124. EISAI Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 125. EISAI Recent Development
Table 126. Sunesis Pharmaceuticals Company Details
Table 127. Sunesis Pharmaceuticals Business Overview
Table 128. Sunesis Pharmaceuticals Product
Table 129. Sunesis Pharmaceuticals Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 130. Sunesis Pharmaceuticals Recent Development
Table 131. Bristol-Myers Squibb Company Details
Table 132. Bristol-Myers Squibb Business Overview
Table 133. Bristol-Myers Squibb Product
Table 134. Bristol-Myers Squibb Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 135. Bristol-Myers Squibb Recent Development
Table 136. Spectrum Pharmaceuticals Company Details
Table 137. Spectrum Pharmaceuticals Business Overview
Table 138. Spectrum Pharmaceuticals Product
Table 139. Spectrum Pharmaceuticals Revenue in Leukemia Cancer Business (2015-2020) (Million US$)
Table 140. Spectrum Pharmaceuticals Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Leukemia Cancer Market Share by Type: 2020 VS 2026
Figure 2. Acute Myeloid Leukaemia (AML) Features
Figure 3. Chronic Myeloid Leukaemia (CML) Features
Figure 4. Acute Lymphoblastic Leukaemia (ALL) Features
Figure 5. Chronic Lymphocytic Leukaemia (CLL) Features
Figure 6. Global Leukemia Cancer Market Share by Application: 2020 VS 2026
Figure 7. Chemotherapy Case Studies
Figure 8. Radiation Therapy Case Studies
Figure 9. Targeted Therapy Case Studies
Figure 10. Biological Therapy Case Studies
Figure 11. Stem Cell Transplant Case Studies
Figure 12. Leukemia Cancer Report Years Considered
Figure 13. Global Leukemia Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Leukemia Cancer Market Share by Regions: 2020 VS 2026
Figure 15. Global Leukemia Cancer Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Leukemia Cancer Market Share by Players in 2019
Figure 18. Global Top Leukemia Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leukemia Cancer as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Leukemia Cancer Revenue in 2019
Figure 20. North America Leukemia Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Leukemia Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Leukemia Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Leukemia Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Leukemia Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Leukemia Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Leukemia Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
急性骨髄性白血病の世界市場（～2026年） Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical …- 急性骨髄性白血病治療薬の世界市場（～2026年） Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90…
- 慢性リンパ性白血病（CLL）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Chronic Lymphocytic Leukemia Therapeutics Market The global Chronic Lymphocytic Leukemia Therapeutics market size is projected to reach US$ 9390.9 million by 2026, from US$ 8411.2 million in 2020, at a CAGR of 10.8%% during 2021-2026. Global Chronic Lymphocytic L…
- 再発急性骨髄性白血病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Relapsed Acute Myeloid Leukemia Drug Market The global Relapsed Acute Myeloid Leukemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Relapsed Acute Myeloid Leukemia Drug Scop…
- 慢性リンパ性白血病（CLL）治療の世界市場（～2026年） Accumulation of functionally incompetent monocytes is referred as Chronic Lymphocytic Leukemia (CLL). Chronic Lymphocytic Leukemia is a type of monoclonal disorder and is commonly found in adults in western countries. Based on the severity, patients diagnosed with chronic lymphocytic leukemia die wi…